RJFSA
DFTX

Raymond James Financial Services Advisors’s Definium Therapeutics DFTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$72.8K Hold
12,789
– – ﹤0.01% 3328
2024
Q2 		$92.2K Sell
12,789
-973
-7% -$8.51K ﹤0.01% 3245
2024
Q1 		$129K Buy
+13,762
New +$78.5K ﹤0.01% 3189
2021
Q3 		– Sell
-703
Closed -$36K – 3369
2021
Q2 		$36K Buy
+703
New +$36.9K ﹤0.01% 3230

Other funds holding DFTX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's DFTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors held its Definium Therapeutics (DFTX) position steady in Q3 2024 at 12,789 shares worth $72.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3328.

Raymond James Financial Services Advisors first reported a position in DFTX in Q2 2021 and has held it in 4 quarters since. The position peaked at $129K in Q1 2024. 157 funds tracked by Wall St. Rank hold DFTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 12,789 shares of Definium Therapeutics worth $72.8K as of Q3 2024.
  • Raymond James Financial Services Advisors left its Definium Therapeutics share count unchanged in Q3 2024.
  • Definium Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3328 holding.
  • Raymond James Financial Services Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Raymond James Financial Services Advisors's Definium Therapeutics position peaked at $129K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.